The Food and Drug Administration is escalating its campaign to ensure drug developers report clinical trial results, sending over 2,200 letters to manufacturers and researchers who have failed to publish data on ClinicalTrials.gov. Commissioner Dr. Marty Makary emphasized that companies have a moral duty to share all results, including unfavorable findings that might affect treatment decisions.

For years, roughly 30 percent of studies analyzed by the FDA lacked reported results, creating gaps in the evidence base physicians rely on. The agency has tools to enforce compliance, including daily fines exceeding $10,000 for late reporting, though it has chosen a voluntary approach for now. Critics argue this "pretty please" strategy falls short of the agency's enforcement capabilities.

Industry watchdogs like Christopher Morten from NYU School of Law worry the effort may be "more symbolic than substantive," while medical ethicists stress that incomplete data misleads doctors and patients. The FDA plans to use artificial intelligence to identify non-compliant studies and will eventually issue formal warnings. This push follows a 2007 law requiring trial reporting after the Vioxx scandal, when Merck faced criticism for withholding heart attack risk data.